TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29169472
Drug: Hypothermia treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermia treatment alone
Study: 24355401
Drug: IOP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IOP treatment as usual (TAU)
Study: 20865421
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment (first-time)
Study: 20218030
Drug: Control activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control activity (2 drug-profile reviews)
Study: 11376174
Drug: No radiotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: No radiotherapy, second surgery, or chemotherapy
Study: 9279624
Drug: One or
Normalized name: Geone Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: One or more doses of BCG vaccine
Study: 9279624
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of BCG vaccine
Study: 9279624
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of BCG vaccine
Study: 9279624
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of BCG vaccine
Study: 25736912
Drug: CHOP-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP-based chemotherapy
Study: 2545451
Drug: RIT-4237 rotavirus
Normalized name: ROTAVIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIT-4237 rotavirus vaccine
Study: 30698771
Drug: Radial Extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial Extracorporeal Shock Wave Therapy (3 sessions)
Study: 29119960
Drug: Low-frequency electrostatic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency electrostatic therapy
Study: 25850708
Drug: Topical Loteprednol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Loteprednol Etabonate 0.5%
Study: 19920107
Drug: Pegfilgrastim (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim (100 mcg/kg, single dose)
Study: 19920107
Drug: Filgrastim (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgrastim (5 mcg/kg/day, daily until neutrophil recovery)
Study: 16491284
Drug: Pamidronate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate treatment (annual dose, 9 mg/kg body weight) for 2-4 years
Study: 15187818
Drug: Wheat fibre
Normalized name: triticum (wheat fibre)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat fibre supplementation (10.5 g/day for 1 week, then 21 g/day for 4 weeks)
Study: 9248263
Drug: 0.5 w/v%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 w/v% black tea extract gargle twice daily (at 8 a.m. and 5 p.m.)
Study: 8448094
Drug: Low-dose epinephrine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose epinephrine
Study: 2360502
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 to 100 mg once daily)
Study: 2427841
Drug: Celiprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (200 to 400 mg once daily)
Study: 25680597
Drug: Pelvic external
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic external beam radiation therapy (EBRT)
Study: 23553459
Drug: Esomeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (40 mg, twice daily) for 12 weeks
Study: 18445988
Drug: imidafenacin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: imidafenacin 0.1 mg twice daily
Study: 12756930
Drug: 4 weeks
Normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks of physical therapy (heat application, massage, ultrasound, muscle stretching)
Study: 12756930
Drug: 6 weeks
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 weeks of physical therapy (heat application, massage, ultrasound, muscle stretching)
Study: 12756930
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (4 weeks and 6 weeks of physical therapy)
Study: 12756930
Drug: 4 weeks
Normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks of physical therapy
Study: 29857780
Drug: 1% N-chlorotaurine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% N-chlorotaurine (NCT) inhaled solution, 1.2 ml over 10 min, once daily for 5 days.
Study: 29857780
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl (placebo) inhaled solution, 1.2 ml over 10 min, once daily for 5 days.
Study: 29857780
Drug: 1% N-chlorotaurine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% N-chlorotaurine (NCT) inhaled solution
Study: 29857780
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl (placebo) inhaled solution
Study: 27163497
Drug: Orteronel 400
Normalized name: Orteronel
DrugBank: Orteronel (DB12066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orteronel 400 mg with a low-fat meal
Study: 27163497
Drug: Orteronel 400
Normalized name: Orteronel
DrugBank: Orteronel (DB12066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orteronel 400 mg with a high-fat meal
Study: 27163497
Drug: Orteronel 400
Normalized name: Orteronel
DrugBank: Orteronel (DB12066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orteronel 400 mg under fasting conditions
Study: 17653960
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg topical testosterone therapy daily (2 cm Andro‐Feme cream)
Study: 16173911
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment arms (including control)
Study: 8084808
Drug: Propranolol 160
Normalized name: propranolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 160 mg daily
Study: 15488139
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (medical treatment only)
Study: 29699518
Drug: Ophthalmic viscosurgical
Normalized name: Viscoat Ophthalmic Viscosurgical Device Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic viscosurgical device (OVD)
Study: 27929610
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (0.5 mg/kg over 40 minutes)
Study: 21734063
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine administered with HPV-16/18 AS04-adjuvanted vaccine (HepB+HPV group)
Study: 21734063
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine administered alone (HepB group)
Study: 19712717
Drug: flavored solution
Normalized name: Benecalorie Unflavored Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: flavored solution consumed prior to 30 min running exercise
Study: 19712717
Drug: flavored solution
Normalized name: Benecalorie Unflavored Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: flavored solution merely tasted prior to 30 min running exercise
Study: 16672064
Drug: Tetracaine 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracaine 4% gel (1.1 g applied for 30 minutes)
Study: 16672064
Drug: Placebo (1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1.1 g applied for 30 minutes)
Study: 16672064
Drug: Tetracaine 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracaine 4% gel
Study: 11230783
Drug: L-NMMA (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (0.1 mg/kg/min) during insulin infusion
Study: 11230783
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (40 mU/m2/min for young, 34 mU/m2/min for old)
Study: 9259113
Drug: Sulodexide (Sdx,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulodexide (Sdx, 50 mg bid orally for 6 months)
Study: 9259113
Drug: Pentoxifylline (Ptx,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (Ptx, 400 mg tid orally for six months)
Study: 576833
Drug: Reproterol (Bronchspasmin)
Normalized name: reproterol
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reproterol (Bronchspasmin) administered at doses of 3 x 20 mg/day (some patients received 6 x 10 mg/day) for four weeks
Study: 576833
Drug: Orciprenaline administered
Normalized name: orciprenaline
DrugBank: Orciprenaline (DB00816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orciprenaline administered at doses of 3 x 20 mg/day (some patients received 6 x 10 mg/day) for four weeks
Study: 24936126
Drug: ETV 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETV 0.5 mg daily
Study: 24936126
Drug: ETV 1
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ETV 1 mg daily
Study: 7603605
Drug: sCT suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: sCT suppositories at the dose of 100 UI/day
Study: 7603605
Drug: sCT suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: sCT suppositories at the dose of 200 UI every other day
Study: 30893166
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sublative bipolar fractional radiofrequency (FRF) and 0.1% topical tretinoin
Study: 2227085
Drug: 0.1% topical
Normalized name: Halog 0.1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% topical tretinoin
Study: 28416587
Drug: Inhaled long-acting
Normalized name: Sinex Long-Acting Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled long-acting beta2-agonist (vilanterol 25 µg)
Study: 28416587
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid (fluticasone furoate 100 µg)
Study: 28416587
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (fluticasone furoate 100 µg and vilanterol 25 µg)
Study: 23315402
Drug: Oral feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral feedback with written information
Study: 23315402
Drug: Oral feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral feedback only
Study: 21977857
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine plus rehabilitation
Study: 21977857
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine plus acupuncture
Study: 21977857
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine and acupuncture plus rehabilitation
Study: 21977857
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine piracetam
Study: 17074146
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (aspirin, clopidogrel)
Study: 15639697
Drug: Rosuvastatin 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 80 mg/d alone (n = 69)
Study: 15639697
Drug: Rosuvastatin 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 80 mg/d plus cholestyramine 16 g/d (n = 75)
Study: 15639697
Drug: Rosuvastatin 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 80 mg/d plus cholestyramine 16 g/d
Study: 15639697
Drug: Rosuvastatin 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 80 mg/d alone
Study: 11508705
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg/kg) in rats
Study: 11508705
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg/kg) in athletes
Study: 3325092
Drug: Nocturnal dosing
Normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nocturnal dosing with levodopa
Study: 20919606
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate 7.2%‐tretinoin 0.025% gel (CTG) combination product
Study: 20919606
Drug: Separate daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate daily applications of clindamycin phosphate gel 1% and tretinoin cream 0.025% (C gel + T cream)
Study: 12538365
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 4 mg kg(‐1) h(‐1) (Group A)
Study: 12538365
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 5 mg kg(‐1) h(‐1) (Group B)
Study: 12538365
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 6 mg kg(‐1) h(‐1) (Group C)
Study: 6234015
Drug: Isotretinoin (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin (0.05 mg/kg/day)
Study: 6234015
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (5 mg daily)
Study: 26748629
Drug: Pancrelipase replacement
Normalized name: Pancrelipase amylase
DrugBank: Pancrelipase amylase (DB11065)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancrelipase replacement therapy
Study: 26748629
Drug: Crossover to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover to pancrelipase replacement therapy upon NAFLD diagnosis in control group
Study: 16776752
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine therapy
Study: 22413808
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma glucose > 10 mmol/l at week 6/8 or week 12
Study: 22413808
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma glucose < 8.9 mmol/l at week 6/8 or week 12
Study: 15126526
Drug: L-T(4) replacement
Normalized name: L-3972-T
DrugBank: L-3972-T (DB17441)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-T(4) replacement therapy
Study: 3388180
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia with parenteral morphine (GA group)
Study: 3388180
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia combined with epidural bupivacaine and epidural morphine (EP group)
Study: 30142849
Drug: Ultralow-dose CT
Normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultralow-dose CT (ULDCT)
Study: 30142849
Drug: Standard low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard low-dose CT (LDCT)
Study: 23887766
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of 12 mg triamcinolone acetonide at the end of surgery
Study: 23887766
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no steroid injection)
Study: 20002501
Drug: Fluconazole (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (800 mg/day)
Study: 12829925
Drug: Low-dose calcitriol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose calcitriol
Study: 12829925
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard immunosuppressive therapy)
Study: 9715320
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with antibiotics
Study: 9199120
Drug: Combined method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined method (surgery and radiotherapy) with moderate postoperative dose of irradiation (5500-6000 cGy)
Study: 9199120
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated by radical neck dissection (RND), modified neck dissection (MND), or regional modified neck dissection (RMND) with moderate postoperative dose of irradiation (5000-5500 cGy)
Study: 1946180
Drug: Ordinary syringe
Normalized name: ordinary salt combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary syringe (4 IU/ml)
Study: 1946180
Drug: Injection pen
Normalized name: Albiglutide 30 mg powder for solution for injection pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection pen (12 IU/ml)
Study: 21175276
Drug: Computer-guided GIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-guided GIN therapy (GINCS)
Study: 21175276
Drug: Manually controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manually controlled GIN therapy
Study: 19724043
Drug: Mass distribution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass distribution of oral azithromycin (1 g for adults, 20 mg/kg for children) administered to communities with over 80% coverage for children aged 1 to 9 years.
Study: 19724043
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment for 1 year) with 18,498 participants.
Study: 12714876
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day lercanidipine (n = 48)
Study: 12714876
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day amlodipine (n = 44)
Study: 1909286
Drug: Persumbran (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persumbran (25 mg dipyridamole + 10 mg oxazepam)
Study: 24836352
Drug: Enalapril/lercanidipine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril/lercanidipine combination (20/10 mg)
Study: 24836352
Drug: Lercanidipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine (10 mg)
Study: 17589951
Drug: Two-week triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-week triple therapy for H pylori eradication
Study: 12209373
Drug: Riboflavin supplementation
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riboflavin supplementation (1.6 mg/day) for 12 weeks
Study: 12209373
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (400 micro g/day) for 6 weeks followed by folic acid and riboflavin (1.6 mg/day) for 12 weeks
Study: 8691860
Drug: Methylprednisolone 25
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone 25 mg/kg body weight
Study: 1809790
Drug: 2% cyclosporine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% cyclosporine ophthalmic ointment (dosed once, twice, or thrice daily for 14 days)
Study: 6135720
Drug: Estazolam 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estazolam 0.25 mg
Study: 6135720
Drug: Estazolam 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estazolam 0.5 mg
Study: 6135720
Drug: Estazolam 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estazolam 1.0 mg
Study: 31256191
Drug: Active shoulder
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active shoulder exercise with a sling suspension system
Study: 25203806
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 13 to 15 mg/kg/d for 4 weeks
Study: 19256150
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g vegetable protein diet
Study: 19256150
Drug: Vegetable protein
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetable protein diet plus 3 g/day of oral kanamycin
Study: 24370801
Drug: Low-dose fentanyl
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fentanyl
Study: 20438741
Drug: Modified sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified sham feeding (MSF) with cherry Kool Aid solutions sweetened with aspartame at concentrations of 0, 0.01, 0.03, 0.08 and 0.28%
Study: 18434268
Drug: Lornoxicam i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam i.v. 8 mg 20 min before incision (Group PRE)
Study: 18434268
Drug: Saline i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline i.v. 20 mins before incision and lornoxicam i.v. 8 mg after skin closure (Group POST)
Study: 16435640
Drug: Submucosal-administered meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submucosal-administered meperidine (0.5 mg/lb) with oral hydroxyzine (0.5 mg/lb)
Study: 16435640
Drug: Oral-administered meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-administered meperidine (1 mg/lb) with oral hydroxyzine (0.5 mg/lb)
Study: 16435640
Drug: Submucosal-administered meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submucosal-administered meperidine (0.5 mg/lb)
Study: 16435640
Drug: Oral-administered meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-administered meperidine (1 mg/lb)
Study: 12805247
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day vitamin C
Study: 12805247
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day vitamin C
Study: 11568777
Drug: Raloxifene 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 150 mg daily
Study: 10374220
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens 0.625 mg daily
Study: 1800394
Drug: Nifedipine alone
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine alone (15-60 mg)